What is Harvard Bioscience?
Harvard Bioscience, Inc. is a prominent entity in the life sciences industry, dedicated to developing, manufacturing, and selling advanced technologies, products, and services. These offerings are crucial for fundamental breakthroughs in research, pharmaceutical and therapy discovery, bio-production, and preclinical testing. The company serves a diverse clientele, including prestigious academic institutions, government laboratories, and leading global pharmaceutical, biotechnology, and contract research organizations. With a strategic international presence spanning the United States, Europe, and China, Harvard Bioscience utilizes a combination of direct sales and distribution channels to reach a worldwide customer base, solidifying its role as a key enabler of scientific progress.
How much funding has Harvard Bioscience raised?
Harvard Bioscience has raised a total of $156.4M across 3 funding rounds:
Stock Offering
$51.4M
Debt
$65M
Debt
$40M
Stock Issuance/Offering (2000): $51.4M, investors not publicly disclosed
Debt (2020): $65M led by Citizens Bank
Debt (2025): $40M supported by BroadOak Capital Partners
Key Investors in Harvard Bioscience
Citizens Bank
Citizens Bank, a major financial institution, provided debt financing to Harvard Bioscience. Their involvement suggests a strong belief in the company's financial stability and growth potential, typical for established banks supporting enterprise-level operations.
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies. Their participation in this undisclosed funding round indicates a strategic focus on early-stage and growth-stage companies within the sector.
What's next for Harvard Bioscience?
The recent major strategic investment into Harvard Bioscience, alongside its substantial total funding, positions the company for significant future expansion and innovation. This capital infusion is likely to fuel further research and development initiatives, enhance manufacturing capabilities, and potentially support strategic acquisitions within the competitive life sciences market. The company's established track record and broad customer base suggest a continued trajectory of growth, with a focus on solidifying its market leadership and advancing critical scientific applications. Future endeavors will likely concentrate on leveraging these resources to accelerate the delivery of novel solutions to its global clientele.
See full Harvard Bioscience company page
